Research
Hormonal
Semaglutide significantly reduced the risk of major limb events (LEs) compared with control interventions, with an odds ratio of 0.70 (95% CI 0.60–0.82; P < 0.0001).
Semaglutide may be an effective treatment option for reducing the risk of PAD-related complications in patients with diabetes or obesity.
StrongSupportsmedium confidence
Semaglutide significantly reduced the risk of LEs compared with control interventions (OR 0.70; 95% CI 0.60–0.82; P < 0.0001).
Why this rating
Based on a meta-analysis of 19 randomized controlled trials.
Source
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Arturo Cesaro et al. · European Journal of Preventive Cardiology · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →